A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome
published in: Journal of Neurodevelopmental Disorders
date of publication: 2019-08-02
main subject: fragile X syndrome
Cites articles 38
Date
Title
Article - wd:Q92347797